Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines

•CRC remains a leading cause of cancer-related deaths globally, despite improvements in management.•Mutations the BRAF gene are seen 10% patients with mCRC, particularly due to V600E substitution.•V600E substitution is marker poor prognosis and reduced response treatment mCRC.•Combination involving MAPK pathway blockade has shown promise for V600E-mutated mCRC.•Continued research needed further improve outcomes these patients. BackgroundColorectal cancer (CRC) still United States worldwide, recent management. CRC, like many malignancies, heterogeneous disease, subtypes characterized by genetic alterations. One common mutation CRC (most commonly substitution). This occurs ∼10% metastatic (mCRC) prognosis.DesignHerein, we review clinical translational literature on role pathogenesis its mechanisms as prognostic marker, potential utility predictive response. We then summarize current evidence-based recommendations management focus advances this setting.ResultsThe standard therapies first-line BRAF-mutated mCRC chemotherapy bevacizumab well 5-fluorouracil, leucovorin, oxaliplatin, irinotecan (FOLFOXIRI) plus good performance status. Combination strategies mitogen-activated protein kinase (MAPK) have promising results mCRC. The Binimetinib, Encorafenib, And Cetuximab cOmbiNed treat BRAF-mutant ColoRectal Cancer (BEACON CRC) study represents largest population date given strong evidence support epidermal growth factor receptor inhibition combination encorafenib cetuximab.ConclusionsThe evolved rapidly over last several years. Recently, other targets continue be explored. In addition, greater understanding should also fuel harboring aberration. Colorectal prognosis. Herein, setting. cetuximab.